ClinicalTrials.gg
Drug

Erlotinib clinical trials

Also written Tarceva, OSI-774 and CP-358,774.

studies test it
507
open now
11
in phase 3
49
first study started
2001

How each study uses erlotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the erlotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Nov 2004 · TARCEVA · NDA 021743 (FDA, Drugs@FDA)
European Union
19 Sept 2005 · Tarceva · EMEA/H/C/000618 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Erlotinib
292
erlotinib hydrochloride
165
erlotinib [Tarceva]
16
Erlotinib (Tarceva)
12
Tarceva (erlotinib HCl)
4

Brand

Tarceva
228

Development codes

OSI-774
131
CP-358,774
75
CP358774
2

In one entry with another drug

Given together, or one or the other

bevacizumab, erlotinib
3
Erlotinib + Sirolimus
2
Bevacizumab and Erlotinib
2

Studies by the year they started

503 studies that test it; most in 2006 (67); 2 more planned to start later

Studies that test erlotinib, by start year
YearStudies
200110
200227
200321
200430
200541
200667
200761
200849
200949
201023
201131
201221
201318
201417
201512
20168
20177
20182
20201
20211
20221
20231
20241
20253
20261

Who runs them

Industry 77 · Other 430

National Cancer Institute (NCI) (63) · Hoffmann-La Roche (36) · M.D. Anderson Cancer Center (35) · OSI Pharmaceuticals (12) · SCRI Development Innovations, LLC (10) · Genentech, Inc. (9) · Memorial Sloan Kettering Cancer Center (9) · Dana-Farber Cancer Institute (8)

Often tested with

Tested in the same studies.

Bevacizumab (64) · Gemcitabine (36) · Docetaxel (18) · Capecitabine (17) · Pemetrexed (15) · Cisplatin (14) · Sorafenib (13) · Carboplatin (12)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Erlotinib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 3

Studies that test erlotinib.

Studies

Open first, then newest update. How each study uses erlotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 507

See all 507 studies that test erlotinib →

Given beside what is tested · 164 — erlotinib is usual care or a partner of the new treatment

Showing 20 of 164.

As the comparator · 15 — what is tested is compared with erlotinib

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call erlotinib · ClinicalTrials.gg INT006571

  • MeSH (NLM) D000069347Erlotinib HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) J4T82NDH7EERLOTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 337525Confirmed FDA, Wikidata
  • Wikidata Q418369erlotinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C65530ErlotinibOne source FDA
  • DrugBank DB00530One source Wikidata

Also registered as erlotinib hydrochloride (UNII DA87705X9K · RxNorm 477320).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.